FOXP3 and experimental autoimmune encephalomyelitis: pDCs can attenuate autoimmune diseases, such as experimental autoimmune encephalomyelitis, by presenting MHC II‐mediated antigens (Ag) to IL‐17‐ and IFN‐γ‐secreting effector CD4+ T cells in secondary lymphoid tissue and by promoting a selective expansion of Ag‐specific forkhead box P3 (Foxp3+) Treg cells.81